Algert Global’s Utah Medical Products UTMD Stock Holding History

Algert Global’s Portfolio UTMD Stock Details UTMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-4,120	Closed	-$342K	–	395
2018 Q4	$342K	Buy	+4,120	New	+$363K	0.1%	267

Other funds holding UTMD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Algert Global's UTMD Position: Q1 2019 in Review

Algert Global sold out of Utah Medical Products (UTMD) in Q1 2019, closing a stake of 4,120 shares — an estimated $342K sold.

Algert Global first reported a position in UTMD in Q4 2018 and held it in 1 quarter. The position peaked at $342K in Q4 2018. 92 funds tracked by Wall St. Rank hold UTMD as of Q1 2019.

Algert Global reported no remaining Utah Medical Products position as of Q1 2019 after selling out during the quarter.
Algert Global sold 4,120 Utah Medical Products shares in Q1 2019, an estimated $342K.
Algert Global first reported a position in Utah Medical Products in Q4 2018 and held it in 1 quarter.
Algert Global's Utah Medical Products position peaked at $342K in Q4 2018.
92 funds tracked by Wall St. Rank held Utah Medical Products as of Q1 2019.

Based on Algert Global's 13F filing for Q1 2019, filed 1 May 2019.